Axovant Sciences (AXON) Trading 7.3% Higher

Axovant Sciences Ltd (NASDAQ:AXON) traded up 7.3% on Thursday . The stock traded as high as $1.78 and last traded at $1.77. 621,025 shares were traded during mid-day trading, a decline of 74% from the average session volume of 2,402,244 shares. The stock had previously closed at $1.65.

AXON has been the topic of several recent analyst reports. Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. BidaskClub cut Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 8th. ValuEngine upgraded Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Cowen restated a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. Axovant Sciences currently has an average rating of “Hold” and a consensus price target of $4.56.

The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.68.



A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its stake in Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 58,541 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock valued at $1,354,000 after buying an additional 64,152 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Axovant Sciences during the second quarter valued at approximately $338,000. Paloma Partners Management Co acquired a new stake in Axovant Sciences during the second quarter valued at approximately $356,000. Finally, BlackRock Inc. raised its stake in Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock valued at $3,447,000 after buying an additional 169,918 shares in the last quarter. Hedge funds and other institutional investors own 7.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/12/07/axovant-sciences-axon-trading-7-3-higher.html.

Axovant Sciences Company Profile (NASDAQ:AXON)

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Story: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply